Tabloid
(Thioguanine)ApprovedSmall molecule
Akero TherapeuticsThioguanine is used to treat certain types of leukemia (blood cancer) by slowing or stopping the growth of cancer cells in the bone marrow.[2] Tabloid is currently approved and in use across 19 indications[4].[1]
Tabloid is one of 358 small molecule programs targeting Non-Hodgkins Lymphoma. It is currently in Approved.
19
Indications
76
Total Trials
18
Active Trials
357
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 19 indications
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Tabloid
Akero TherapeuticsApproved
Oncaspar
SServier
Preclinical
Wellcovorin
GGlaxo Dba Glaxosmithkline
Preclinical
Tafasitamab
IncytePreclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
CAR-T
HHebei Senlang Biotechnology Inc., Ltd.
Preclinical
Stem Cells
KKang Stem Biotech Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia39 trials
Show 36 more trials
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Unknown status·—·Phase 3·NCT00764907·4,000 enrolled
Lymphoblastic Lymphoma6 trials
Show 3 more trials
B Acute Lymphoblastic Leukemia4 trials
Leukemia3 trials
15 more indications
T-cell acute lymphoblastic leukemia3 trials
Myelodysplastic Syndrome3 trials
Lymphoma2 trials
Acute Myeloid Leukemia2 trials
Acute Promyelocytic Leukemia1 trial
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002701·750 enrolled
Myeloproliferative Disorder1 trial
R/R AML1 trial
DEC-C and Thioguanine for R/R AML
Withdrawn·—·Phase 2·NCT06351306
Myelodysplastic Syndromes1 trial
B-cell acute lymphoblastic leukemia1 trial
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
THIOGUANINE
NDA NDA012429
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Tabloid drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Thioguanine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Inosine-5'-Monophosphate Dehydrogenase (IMPDH) Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company